QURE Key Statistics, Chart & Performance
The current stock price of QURE is 25.08 USD. In the past month the price increased by 3.72%. In the past year, price increased by 60.05%.
QURE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to QURE. When comparing the yearly performance of all stocks, QURE turns out to be only a medium performer in the overall market: it outperformed 42.34% of all stocks.
QURE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to QURE. QURE has a bad profitability rating. Also its financial health evaluation is rather negative.
QURE Financial Highlights
Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 11.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.47% | ||
| ROE | -102.8% | ||
| Debt/Equity | 2.26 |
QURE Forecast & Estimates
20 analysts have analysed QURE and the average price target is 54.25 USD. This implies a price increase of 116.29% is expected in the next year compared to the current price of 25.08.
For the next year, analysts expect an EPS growth of 19.6% and a revenue growth -60.9% for QURE
QURE Ownership
About QURE
Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP NL
CEO: Matthew Kapusta
Employees: 209
Phone: 31202406000
UNIQURE NV / QURE FAQ
Can you describe the business of UNIQURE NV?
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
What is the current price of QURE stock?
The current stock price of QURE is 25.08 USD. The price increased by 10.53% in the last trading session.
Does QURE stock pay dividends?
QURE does not pay a dividend.
What is the ChartMill technical and fundamental rating of QURE stock?
QURE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is UNIQURE NV worth?
UNIQURE NV (QURE) has a market capitalization of 1.56B USD. This makes QURE a Small Cap stock.
Who owns UNIQURE NV?
You can find the ownership structure of UNIQURE NV (QURE) on the Ownership tab.